In this exclusive interview, Jess Fertig hosts James McDonnell, CEO of Prescient Therapeutics (ASX: PTX), a biotech innovator in the healthcare sector. Discover how PTX's lead asset, PTX 100, is advancing through crucial Phase 2 trials targeting cutaneous T cell lymphoma (CTCL), with promising response rates and minimal serious adverse events. James shares insights into the company's strategic pathway, including FDA fast track designation and potential market opportunities exceeding $1.8 billion. Learn how PTX's targeted Ras pathway disruption could unlock new treatments for multiple cancers like lung, pancreatic, and biliary tumours. The conversation also covers funding strategies, the impact of government R&D incentives, and upcoming milestones that could accelerate PTX’s journey to market. Whether you're an early stage biotech investor or interested in innovative cancer therapies, this interview provides valuable insights into PTX’s potential to revolutionise oncology care. Watch till the end for key investment highlights and why Prescient Therapeutics should be on your watchlist.

📅 Timestamps:
0:02 Introduction
1:07 PTX Overview & Focus
3:14 PTX 100 Results & Safety
4:38 FDA Fast Track & Market Access
8:02 Market Opportunity & Future Potential
10:04 Development & Funding
14:03 Investment Highlights

🚨 Disclaimer: This content is for informational purposes only and does not constitute financial advice. Please conduct your own research before investing.

📌 Articles:
https://smallcaps.com.au/prescient-therapeutics-ptx-100-phase-2a-trials-outstanding-results/
https://smallcaps.com.au/prescient-therapeutics-fast-track-fda-ptx-100-t-cell-lymphoma/

🔎 More on Prescient Therapeutics:
https://smallcaps.com.au/stocks/asx-ptx/

See omnystudio.com/listener for privacy information.

In this exclusive interview, Jess Fertig welcomes Andrew Vigar, Chairman of Terra Uranium (ASX: T92.ASX), to discuss the company's exciting strategic moves into critical minerals like tungsten, tin, molybdenum, and bismuth. Discover how Terra Uranium is leveraging innovative technologies such as optical sorting to unlock the potential of the Glen Eden project—the largest undeveloped tungsten asset in NSW—and how recent capital raises are funding exploration efforts. Andrew breaks down the significance of the projects, their scale, and the company's vision to create a globally significant resource portfolio in Australia. Plus, insights into government support, environmental advantages of modern processing, and the company's long-term growth strategy. Stay tuned for key investment highlights and why Terra Uranium could be a major player in the critical minerals space.

Don't forget to subscribe to Small Caps for more interviews with emerging ASX stocks! 🚀

*Disclaimer: This video is for informational purposes only and does not constitute financial advice. Please conduct your own research before investing.*

📌 Articles:
https://smallcaps.com.au/terra-uranium-to-acquire-undeveloped-tungsten-tin-molybdenum-project-in-nsw/
https://smallcaps.com.au/terra-uranium-drilling-campaigns-spire-horizon-positive-survey-data/

🔎 More on Terra Uranium:
https://smallcaps.com.au/stocks/asx-T92/

See omnystudio.com/listener for privacy information.

In this exclusive interview, Rita Brooks, Exec Chair of Tambourah Metals (ASX: TMB), shares exciting updates on the company's exploration strategies in Western Australia’s renowned gold and critical minerals regions. Discover how Tambourah's drilling program is uncovering high-grade gold, antimony, and silver prospects with tremendous upside potential. With multiple projects, strategic positioning near big deposits like Harmony Gold and Peak Hill, and upcoming results from recent sampling and drilling, Tambourah is set to be a notable player in the booming Australian mineral space. The company's focus on resource development, combined with recent advancements in drill testing and regional positioning, provides compelling reasons to watch TMB as key news flows unfold. Don't miss out — like, subscribe, and stay tuned for more insights on this promising ASX small-cap in the materials sector! 🚀💰

Please note: This is not financial advice. Always do your own research or consult with a financial advisor before investing.

Timestamps:
0:06 Small caps overview
0:17 Drilling at Betty / BT Park
1:10 Significance of high-grade gold results
2:18 Antimony sampling at Speedway North
4:55 Bulk sampling at Tambina
6:31 Resource potential at Tambourah
8:06 Historic prospects and upside
10:46 Entitlement offer close details
12:02 Why Tambourah is a stock to watch in 2023!

*Invest responsibly. This video is for informational purposes only and should not be considered financial advice.*

📌 Articles:
https://smallcaps.com.au/tambourah-metals-extends-strike-tambourah-king-gold-drilling/
https://smallcaps.com.au/tambourah-metals-momentum-strong-pilbara-results-drilling-plans/

🔎 More on Tambourah Metals:
https://smallcaps.com.au/stocks/asx-tmb/

See omnystudio.com/listener for privacy information.

In this exclusive interview, Alexander Scanlon, MD & CEO of Barton Gold Holdings (ASX: BGD), sits down with Jess Fertig to reveal the company’s strategic outlook and exciting milestones. Discover how Barton Gold is leveraging its existing infrastructure and regional assets to unlock $2.7 billion in free cash flow, with a pathway to 150,000+ oz annual gold production by 2030.

Key highlights include the Stage 1 & 2 starter pits with rapid payback, the potential of the groundbreaking Thomas silver discovery, and the strategic Wadena nickel project expansion.

Alex discusses financing strategies, project timelines, exploration successes, and how the company’s disciplined approach minimises risk while maximising shareholder value. Barton Gold is positioned for significant growth in the buoyant gold sector. Whether you're a junior explorer investor or seeking diversified gold plays, this insight-packed interview offers essential takeaways.

Don’t miss out on updates and analysis – subscribe to Small Caps for more exclusive content! 📈🔑

Timestamp Highlights:
00:18 - Company overview & milestones
02:56 - Project design & economics
07:08 - Thomas silver discovery potential
11:25 - Wadena project & regional M&A
16:00 - Funding & investor support
24:57 - Capital allocation & growth strategy

*Invest responsibly. This video is for informational purposes only and should not be considered financial advice.*

📌 Articles:
https://smallcaps.com.au/barton-gold-eyre-peninsula-wudinna-project-acquisition/
https://smallcaps.com.au/barton-gold-upgrades-challenger-resource-stage-1-push/

🔎 More on Barton Gold:
https://smallcaps.com.au/stocks/asx-bgd/

See omnystudio.com/listener for privacy information.

EVE Health (ASX: EVE) chief executive officer Damian Wood joins Small Caps to discuss the formation of a strategic clinic partnership with TeleDocs Clinic.

The collaboration agreement will deliver online prescribing access and nationwide opportunities to market an erectile dysfunction oral soluble film and a dysmenorrhea gummy through the strategic clinic partnership.

The agreement includes prescribing and education and will deliver online prescribing access and nationwide pharmacy support for EVE’s oral health portfolio.

TeleDocs Clinic will be the first online clinic authorised to prescribe both products, while working with a network of over 3,500 pharmacies across Australia.

TeleDocs will also work with EVE on developing decision support tools for practitioners and pharmacies, list the products onto major prescribing software platforms, and provide national exposure via newsletters and inclusion in professional education databases.

TeleDocs Clinic’s digital health expertise and network will be critical to launching a new value proposition at scale, where there’s an unmet clinical need

Articles:
https://smallcaps.com.au/eve-health-teledocs-online-prescription-erectile-dysfunction-period-pain-treatments/
https://smallcaps.com.au/eve-health-group-completes-takeover-nextract-strengthens-executive-team/

For more information on EVE Health:
https://smallcaps.com.au/stocks/asx-eve/

See omnystudio.com/listener for privacy information.

NoviqTech (ASX: NVQ) chief executive officer Freddy El Turk joins Small Caps to discuss the AI intelligence and distributed ledger technology specialist's recent corporate moves.

Most recently NoviqTech and Australia's Livium (ASX: LIT) agreed to collaborate to support the tokenisation of environmental benefits from advanced battery recycling operations using NoviqTech’s Carbon Central platform.

The pioneering project aims to establish a new digital framework for tracking and verifying carbon reductions and mineral circularity within Livium's battery recycling operations.

The collaboration will focus on digital tracking and validation of emissions reductions by recycling and reusing existing battery materials in place of mining new resources.

Last month NoviqTech agreed to extend its strategic collaboration with financial, technical, and marketing support provider Hedera Foundation.

The additional 5 years extension will be supported by a milestone-based grant designed to drive accelerated customer growth, enhance platform adoption, and expand transaction scalability across NoviqTech’s blockchain-powered sustainability solutions.

Articles:
https://smallcaps.com.au/noviqtech-five-year-extension-collaboration-hedera-foundation/
https://smallcaps.com.au/noviqtech-livium-digital-battery-recycling-initiative-tokenised-esg/

For more information on NoviqTech:
https://smallcaps.com.au/stocks/asx-nvq/

See omnystudio.com/listener for privacy information.

Altech Batteries (ASX: ATC) chief financial officer and company secretary Martin Stein joins Small Caps to discuss the company's recent successes, highlighting the long life and safety of its ground-breaking CERENERGY technology.

Considered a safer alternative to lithium-ion batteries, the CERENERGY project has received the highest possible rating from S&P Global Ratings and is classified as "Dark Green" in a market that is tipped to reach $386 billion annually in the near future.

Mr Stein discusses Altech's plans to leverage that substantial market, while also highlighting new studies that have confirmed the long life of CERENERGY and the capabilities of its sodium-nickel-chloride (Na-Ni-Cl) technology.

In a recent examination of the Na-Ni-Cl technology’s durability, a 28-year-old Zebra battery—originally manufactured in Berlin and left unused in storage—was provided to Altech for evaluation.

Subsequent testing saw the decades-old battery successfully activated and performing as if it were new, exhibiting no degradation in function or capacity despite nearly three decades of dormancy.

Articles:
https://smallcaps.com.au/altech-batteries-extended-shelf-life-cerenergy-technology/
https://smallcaps.com.au/altech-batteries-cerenergy-emerging-alternative-lithium-ion/

For more information on Altech Batteries:
https://smallcaps.com.au/stocks/asx-atc/

See omnystudio.com/listener for privacy information.

Terra Uranium (ASX: T92) executive chairman Andrew Vigar joins Small Caps to discuss the company's plans to drill at the Spire, Horizon and HawkRock projects in 2025.

A coordinated program has been prepared, with permits in place for the focused 2025 drill program, which will be undertaken across multiple drill-ready targets.

Spire and Horizon are part of a strategic agreement Terra signed with ATHA Energy in 2024 to earn 70% of the uranium projects.

Spire and Horizon comprise 12 mineral claims located on the eastern rim of the Athabasca Basin within the East Rim Exploration District.

The company has also completed geophysical interpretation on its 100%-owned HawkRock exploration project after airborne gravity and magnetic surveys targeted conductive corridors in the field.

The company says it remains well positioned to take advantage of an anticipated recovery in the uranium price, driven by rising demand for sustainable power sources, including AI-driven data centres.

Articles:
https://smallcaps.com.au/terra-uranium-drilling-campaigns-spire-horizon-positive-survey-data/

For more information on Terra Uranium:
https://smallcaps.com.au/stocks/asx-t92/

See omnystudio.com/listener for privacy information.